The study conducted by Herek et al. highlighted that DNMT3A mutations define a cytotoxic subset in PTCL-TBX21 with prognostic value, clarifying the heterogenicity of PTCL-NOS [101]. The gene discussed is DNMT3A; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.